Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia

Pediatr Blood Cancer. 2024 Jun;71(6):e30964. doi: 10.1002/pbc.30964. Epub 2024 Mar 21.

Affiliations

¹ Department of Pediatric Hematology Oncology, University Hospitals Rainbow Babies and Children, Cleveland, Ohio, USA.
² Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
³ Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

PMID: 38514796
DOI: 10.1002/pbc.30964

No abstract available

Publication types

Letter
Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides / therapeutic use
Antibodies, Bispecific* / administration & dosage
Antibodies, Bispecific* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Child
Female
Gene Rearrangement
Histone-Lysine N-Methyltransferase* / genetics
Humans
Immunotherapy, Adoptive* / adverse effects
Immunotherapy, Adoptive* / methods
Male
Myeloid-Lymphoid Leukemia Protein* / genetics
Neoplasms, Second Primary / etiology
Neoplasms, Second Primary / genetics
Piperazines* / therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Pyridines* / administration & dosage
Pyridines* / adverse effects
Pyridines* / therapeutic use

Substances

blinatumomab
Antibodies, Bispecific
Myeloid-Lymphoid Leukemia Protein
KMT2A protein, human
Histone-Lysine N-Methyltransferase
palbociclib
Piperazines
Pyridines
Acrylamides